# FDA recall Z-0267-2018

> **C.R. Bard, Inc.** · Class II · device recall initiated 2016-12-09.

## Product

I-125 CE Marked QuickLink Cartridges; Sterile; Bard Brachysource Radioactive Seeds in QuickLink Cartridges    Indicated for permanent interstitial treatment of selected localized tumors such as: head and neck, lung, pancreas, and early stage prostate. Implants are indicated to treat residual tumors following completion of a course of external radiation therapy and for recurrent tumors.

## Reason for recall

Activity and quantity of seeds sent in shipments were incorrect.

## Distribution

Belgium & South Africa.

## Key facts

- **Recall number:** Z-0267-2018
- **Recalling firm:** C.R. Bard, Inc.
- **Classification:** Class II
- **Product type:** device
- **Status:** Terminated
- **Initiation date:** 2016-12-09
- **Report date:** 2017-12-27
- **Termination date:** 2020-04-24

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Covington, GA, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=Z-0267-2018

## Citation

> AI Analytics. FDA recall Z-0267-2018. Retrieved 2026-06-02 from https://api.ai-analytics.org/recall/Z-0267-2018. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*